Mucosolvan (Ambroxol Hydrochloride)

Ambroxol Hydrochloride stimulates the production of surfactant in the airways and breaks down mucopolysaccharide fibers within mucus. This reduces mucus viscosity, enhances ciliary activity, and promotes more efficient clearance of secretions from the respiratory tract.

The dosage of Mucosolvan is individualized by the prescribing healthcare professional based on the patient’s age, condition severity, and response to therapy. Typical adult regimens may range from 30 mg to 60 mg three times daily, but exact dosing should follow the prescriber’s instructions.

Safety data for Ambroxol Hydrochloride during pregnancy and lactation are limited. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made in consultation with a qualified healthcare provider.

To place an order, submit an enquiry on the Mucosolvan product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mucosolvan (Ambroxol) differs from other mucolytics such as N‑acetylcysteine by primarily stimulating surfactant production and enhancing ciliary function, whereas some alternatives act mainly by breaking disulfide bonds in mucus. Clinical choice depends on patient tolerance, specific indication, and physician preference.

Mucosolvan should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and excessive heat to maintain its stability and efficacy throughout its shelf life.

Mucosolvan is administered orally, typically in tablet or syrup form, as directed by the prescriber. It should be taken with a glass of water, and the dosage schedule should be adhered to for optimal mucus‑clearing effect.

Serious adverse events, although rare, include severe allergic reactions such as rash, angioedema, or Stevens‑Johnson syndrome, as well as significant liver enzyme elevations that may indicate hepatic injury. Immediate medical attention is required if any of these symptoms develop.

Mucosolvan is contraindicated in individuals with known hypersensitivity to ambroxol or any excipients in the formulation. Patients with uncontrolled asthma, severe renal or hepatic impairment, or those who have experienced serious allergic reactions to mucolytics should avoid its use unless advised otherwise by a physician.